Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eprenetapopt + Azacitidine in TP53-Mutant Myeloid Neoplasms
NCT03072043Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- May 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eprenetapopt in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), chronic myelomonocytic leukemia (CMML), sponsored by Moffitt Cancer Center. Started May 2017; status: completed.
02
Drugs
eprenetapopt
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)myeloproliferative neoplasms (MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03072043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072043.